Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder	Active, not recruiting	Phase 1	2026-09-22		NCT04963153

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Los Angeles General Medical Center	Los Angeles	United States	179
Moffitt Cancer Center	Tampa	United States	523
NYP/Weill Cornell Medical Center	New York	United States	128
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
UCHealth University of Colorado Hospital	Aurora	United States	172
University Health Network-Princess Margaret Hospital	Toronto	Canada	88
UPMC Hillman Cancer Center	Pittsburgh	United States	330
USC / Norris Comprehensive Cancer Center	Los Angeles	United States	249
UT Southwestern/Simmons Cancer Center-Dallas	Dallas	United States	273